

Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study

MANUSCRIPT SUMMARY | Quintas et al., 2024

#### **6** OBJECTIVES

Compare the safety and efficacy of Aquablation therapy against holmium laser enucleation (HoLEP).

## **DETAILS**



Spain



150



Multi-Center





AB: 72mL HoLEP: 82 mL


## **METHODS**

- o Prospective comparative, non-randomized, multi-center assessment from July 2021-2023
- Assessment of 150 patients 75 Aquablation therapy and 75 HoLEP
- o Primary outcomes change in IPSS, quality of life, Qmax, PVR, and PSA
- o Secondary outcomes transfusions, continence, ejaculatory function & erectile function

## **♦ RESULTS**







# <u>durability</u>





Aquablation therapy

no report of surgical retreatment in either group

at 6 months

#### **AUTHOR CONCLUSIONS**

Both HoLEP and Aquablation seem effective and safe at six months for the treatment of patients with BPH-related LUTS. Urinary functional outcomes, social urinary continence, and blood transfusion rate do not appear to differ significantly between these techniques. However, Aquablation is associated with a significantly lower ejaculatory dysfunction rate than HoLEP.

Quintas et al., Minerva Urology and Nephrology. 2024